These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 7537518)

  • 1. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.
    Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL
    Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
    Aherne GW; Hardcastle A; Raynaud F; Jackman AL
    Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
    Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
    Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
    Freemantle SJ; Jackman AL; Kelland LR; Calvert AH; Lunec J
    Br J Cancer; 1995 May; 71(5):925-30. PubMed ID: 7537519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.
    Takemura Y; Gibson W; Kimbell R; Kobayashi H; Miyachi H; Jackman AL
    J Cancer Res Clin Oncol; 1996; 122(2):109-17. PubMed ID: 8576277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
    Kelland LR; Kimbell R; Hardcastle A; Aherne GW; Jackman AL
    Eur J Cancer; 1995 Jun; 31A(6):981-6. PubMed ID: 7646933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
    McGuire JJ; Magee KJ; Russell CA; Canestrari JM
    Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.